Last reviewed · How we verify

Aranesp — Competitive Intelligence Brief

Aranesp (Aranesp) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Hematology.

marketed Erythropoietin receptor Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Aranesp (Aranesp) — University of Washington.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aranesp TARGET Aranesp University of Washington marketed Erythropoietin receptor
Eporatio EPOETIN THETA marketed Erythropoietin receptor 2009-01-01
Silapo EPOETIN ZETA Hospira UK Limited marketed Erythropoietin receptor 2007-01-01
Mircera METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA Hoffman-La Roche marketed erythropoietin receptor 2007-01-01
Aranesp DARBEPOETIN ALFA Amgen marketed Erythropoiesis-stimulating Agent [EPC] Erythropoietin receptor 2001-01-01
Neorecormon EPOETIN BETA Roche Registration Limited marketed Erythropoietin receptor 1997-01-01
Epogen Epoetin Alfa-Epbx Amgen marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor 1989-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aranesp — Competitive Intelligence Brief. https://druglandscape.com/ci/aranesp. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: